Abstract: A method for producing a cell having nucleic acid introduced therein and having low cytotoxicity is useful in primary cells and slowly dividing cells, for which nucleic acid introduction is difficult with conventional techniques. A method for introducing nucleic acid into a cell includes the steps of mixing a nucleic acid with a temperature sensitive material at a temperature lower than the cloud point of the temperature sensitive material, the temperature sensitive material being formed by adding 2-amino-2-hydroxymethyl-1,3-propanediol to a temperature-sensitive polymer material having 2-N,N-dimethylaminoethyl methacrylate and/or a derivative thereof as the main polymer component, flow coating a culture vessel with the resulting mixed liquid, and culturing a cell suspension provided to the culture vessel at a temperature higher than the cloud point.

Abstract: The present invention provides a membranous connective tissue-forming substrate on which a membranous connective tissue having a sufficient thickness and strength can be formed and a method for producing a membranous connective tissue by using the substrate. Specifically, a connective tissue-forming section 2 is provided on the surface of the substrate. The connective tissue-forming section 2 is surrounded by a thickness-increasing section 3 to enlarge a membranous connective tissue-forming substrate 1 as a whole. The membranous connective tissue-forming substrate 1 is placed under an environment in which a biological tissue material is present to form a membranous connective tissue on the surface of the substrate. In proportion as the size of the membranous connective tissue-forming substrate 1 increases, the thickness of the membranous connective tissue increases. A surplus portion formed on the surface of the thickness-increasing section 3 is removed from the connective tissue.

Abstract: Contour information is extracted from nuclear medicine projection data on a subject not subjected to a scattering correction and an absorption correction by performing a pixel value binarization processing based on a threshold scheme. If necessary, an interpolation processing is performed before reconstructing an image through an image reconstruction processing. Based on the reconstructed image, a second binarization processing is performed to generate a contour image.

Abstract: An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4?-position and 2?-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.

Abstract: A measuring image acquisition means 2 acquires a 3-D measuring image in which a phantom filled with the radioactive material into a necessary part is measured with a SPECT system. A measuring image Fourier transform means 4 operates the 3-D measuring image with the 3-D Fourier transform. An actual image acquisition means 6 acquires a 3-D actual image of the part of the phantom which is filled with the radioactive material. An actual image Fourier transform means 8 operates a 3-D actual image with the 3-D Fourier transform. An error image calculation means 10 divides each Fourier transform value of the 3-D Fourier transform measuring image by each Fourier transform value of the corresponding 3-D Fourier transform actual image and acquires a 3-D Fourier transform error image. A point spread function calculation means 12 operates the 3-D Fourier transform error image with the inverse Fourier transform and determines the point spread function image by calculation.

Abstract: An object of the present invention is to provide a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc. The present invention provides a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc., the agents etc. comprising desacyl ghrelin or its derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.

Abstract: A monitoring apparatus includes a condition determining section which is configured to determine a condition of one of a heart, lungs, and blood vessels based on: a concentration of carbon dioxide in an expired gas which is measured by using a first sensor; and an oxygen transport parameter or a metabolic parameter which is measured by using a second sensor.

Abstract: An object of the present invention is to provide a therapeutic agent for accelerating recovery to accelerate a return to normal physical conditions by administering to an animal not in good health and under medical treatment, a treatment method, and the like. There is provided a therapeutic agent for accelerating recovery for animal use to accelerate the improvement of a physical condition of an animal under medical treatment which has a decreased activity (vigor) and is exhausted, which contains ghrelin or a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient and improves one or more of evaluation parameters consisting of activity (vigor), blood cell test values, biochemical test values, body temperature, the degree of anger or anxiety, and respiratory rate.

Abstract: An electrostimulation system includes a connector connected to an electrostimulation device, a conducting wire pair electrically connected to the connector, an electrical stimulation lead having a sheathing body configured to insulate the conducting wire pair and installed to be inserted into the vein, an electrical stimulus block portion installed at a leading end side of the electrical stimulation lead and having an electrode portion electrically connected to the conducting wire pair and a fixing block configured to bias the electrode portion to the inner wall of the vein, and a rotary member having an engaging groove detachably engaged with the electrical stimulus block portion and configured to rotate the electrical stimulus block portion disposed in the vein about a central axis of the vein disposed in the vein via the engaging groove.

Abstract: A method for producing a cell having nucleic acid introduced therein and having low cytotoxicity is useful in primary cells and slowly dividing cells, for which nucleic acid introduction is difficult with conventional techniques. A method for introducing nucleic acid into a cell includes the steps of mixing a nucleic acid with a temperature sensitive material at a temperature lower than the cloud point of the temperature sensitive material, the temperature sensitive material being formed by adding 2-amino-2-hydroxymethyl-1,3-propanediol to a temperature-sensitive polymer material having 2-N,N-dimethylaminoethyl methacrylate and/or a derivative thereof as the main polymer component, flow coating a culture vessel with the resulting mixed liquid, and culturing a cell suspension provided to the culture vessel at a temperature higher than the cloud point.

Abstract: A diagnosis assistance apparatus for assisting a diagnosis using schemas includes a storage section that stores a plurality of different schemas each configured by a figure representing a body region, an acquiring section that acquires results of a plurality of examinations that are performed on an examination target, a schema refining section that refines a schema of a body region related to a disease that is predicted from the acquired examination results, from the schemas step-by-step in accordance with progress of the examinations, and a displaying section that displays the schema refined by the schema refining section.

Abstract: A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R1, R2, and R3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.

Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.

Abstract: Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.

Abstract: A left atrial pressure measurement device includes: a measurement section that measures a first index value that indicates performance of a right ventricle, and a second index value that indicates performance of a left ventricle; and a calculation section that calculates a left atrial pressure using the first index value, the second index value, and a measured right atrial pressure.

Abstract: The present invention provides a base material which can be formed into valved lumen shape tissue having an ampulla and a leaflet consisting of body tissue. Specifically, the base material includes a first column 5 that forms an upstream tubular section 4 of a blood vessel 3, a second column 7 that forms a downstream tubular section 6 of the blood vessel 3, a plurality of bulges 10 for forming an ampulla 8 and a leaflet 9 of the blood vessel 3, and engagement means 11 that causes the bulge 10 to engage the first column 5 and/or the second column 7. The engagement means 11 includes recesses 15a and 15b in axial end surfaces of one or both of the first column 5 and the second column 7, and an engagement section 18 that overhangs from a bulge body 17 and engages the recesses. An outer peripheral surface of the body 17 of the bulge 10 is an ampulla forming surface 20, and a gap provided between the bulge body 17 and the first column 5 and/or the second column 7 is a leaflet forming section 22.

Abstract: A medicinal agent for suppressing or preventing the metastasis of a malignant tumor, the agent comprising, as an active ingredient, at least one kind of vascular endothelial intracellular cGMP enhancer.

Abstract: A stent comprising a tubular stent matrix of which diameter is extendable and a flexible polymer layer covering the stent matrix. The polymer layer is closely attached to and covers the entire surface of the stent matrix. Since the flexible polymer layer closely covers the entire surface of the stent matrix not only the outer periphery of the stent matrix, the stent has no problem of causing allergic to metal, stimulus of tissues due to metal, and rust development. Since the inner periphery of the stent is a flat and smooth surface covered by the polymer layer without convexes and concaves, the formation of thrombus can be inhibited well. There is no problem of drift between the polymer layer and the stent matrix, thereby maintaining the positional relationship between the stent matrix and the polymer layer before and after the expansion of the stent.

Abstract: A method of the present invention for producing a calcium phosphate complex including a substrate and calcium phosphate bonded to a surface of the substrate, the method includes the steps of: (a) treating the surface of the substrate; and (b) bonding the calcium phosphate onto the surface of the substrate after the step (a), the step (a) being the step of placing the surface of the substrate in contact with ozone water. Therefore, the method of the present invention makes it possible to bond calcium phosphate and the substrate at a high bonding strength and at a high coverage. In addition, the method of the present invention provides an easy method for producing a calcium phosphate complex.